World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Alzheimer's disease and other dementias

被引:67
作者
Ihl, Ralf [1 ,2 ]
Froelich, Lutz [3 ]
Winblad, Bengt [4 ]
Schneider, Lon [5 ]
Burns, Alistair [6 ]
Moeller, Hans-Juergen [7 ]
机构
[1] Alexian Hosp, Clin Geriatr Psychiat & Psychotherapy, D-47504 Krefeld, Germany
[2] Univ Duesseldorf, Dept Psychiat, Dusseldorf, Germany
[3] Heidelberg Univ, Cent Inst Mental Hlth Mannheim, Div Geriatr Psychiat, D-6800 Mannheim, Germany
[4] Karolinska Inst, Huddinge, Sweden
[5] Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA
[6] Univ Manchester, Psychiat Res Grp, Manchester, Lancs, England
[7] Univ Munich, Dept Psychiat & Psychotherapy, Munich, Germany
关键词
Dementia; guidelines; Alzheimer; vascular dementia; Lewy body disease; fronto-temporal dementia; anti-dementia pharmaceuticals; neuropsychiatric symptoms; NPS; biological; treatment; MILD COGNITIVE IMPAIRMENT; PLACEBO-CONTROLLED TRIAL; MINI-MENTAL-STATE; NURSING-HOME PATIENTS; EXTRACT EGB 761(R); MODERATE VASCULAR DEMENTIA; CONTROLLED CLINICAL-TRIAL; BILOBA SPECIAL EXTRACT; DOUBLE-BLIND; GINKGO-BILOBA;
D O I
10.3109/15622975.2010.538083
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Objectives. To define a practice guideline for biological treatment of dementia and to make transparent the development of the guideline connecting the original data with the resulting recommendations. Methods. This guideline includes pharmacologic treatment considerations for patients with Alzheimer's disease, vascular dementia, DLB, and fronto-temporal dementia. Studies were selected that represent double-blind placebo-controlled trials of at least 3 months duration in patients with a diagnosis of dementia according to accepted international diagnostic criteria (for example the NINCDS/ADRDA or NINDS/AIREN criteria). Moreover, to be included studies had to fulfill a restrictive set of methodological criteria. Original studies and not meta-analyses determined the evaluation and the development of recommendations. Results. Antidementia pharmaceuticals neither cure nor arrest the disease. A modest effect of improvement of symptoms compared with placebo can be observed. Antidementia pharmaceuticals show different efficacy and side effect profiles. The type of dementia, the individual symptom constellation and the tolerability should determine what medication should be used. There are hints that combination therapy of drugs with different therapeutic mechanisms might improve the efficacy. In treating neuropsychiatric symptoms (NPS), psychosocial intervention should be the treatment of first choice. Pharmaceuticals can only be recommended when psychosocial interventions is not adequate. However, even then the side effects of pharmaceuticals limit their use. Conclusions. Depending on the diagnostic entity and the pathology treated different anti-dementia drugs can be recommended to improve symptoms. In the management of NPS, side effects limit the use of medications even when psychosocial interventions have failed. Thus, there is an urgent need to develop more efficacious medications for the treatment of dementia.
引用
收藏
页码:2 / 32
页数:31
相关论文
共 217 条
[71]   Neurological complications of psychiatric drugs: clinical features and management [J].
Haddad, Peter M. ;
Dursun, Serdar M. .
HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 2008, 23 :15-26
[72]   Adverse effects of atypical antipsychotics: Differential risk and clinical implications [J].
Haddad, Peter M. ;
Sharma, Sonu G. .
CNS DRUGS, 2007, 21 (11) :911-936
[73]   Lithium Trial in Alzheimer's Disease: A Randomized, Single-Blind, Placebo-Controlled, Multicenter 10-Week Study [J].
Hampel, Harald ;
Ewers, Michael ;
Buerger, Katharina ;
Annas, Peter ;
Moertberg, Anette ;
Bogstedt, Anna ;
Froelich, Lutz ;
Schroeder, Johannes ;
Schoenknecht, Peter ;
Riepe, Matthias W. ;
Kraft, Inga ;
Gasser, Thomas ;
Leyhe, Thomas ;
Moeller, Hans-Juergen ;
Kurz, Alexander ;
Basun, Hans .
JOURNAL OF CLINICAL PSYCHIATRY, 2009, 70 (06) :922-931
[74]   Pharmacologic management of neuropsychiatric symptoms of Alzheimer disease [J].
Herrmann, Nathan ;
Lanctot, Krista L. .
CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE, 2007, 52 (10) :630-646
[75]   A placebo-controlled trial of valproate for agitation and aggression in Alzheimer's disease [J].
Herrmann, Nathan ;
Lanctot, Krista L. ;
Rothenburg, Lana S. ;
Eryavec, Goran .
DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 2007, 23 (02) :116-119
[76]   Validity of current clinical criteria for Alzheimer's disease, vascular dementia and dementia with Lewy bodies [J].
Holmes, C ;
Cairns, N ;
Lantos, P ;
Mann, A .
BRITISH JOURNAL OF PSYCHIATRY, 1999, 174 :45-50
[77]   Long-term effects of Aβ42 immunisation in Alzheimer's disease:: follow-up of a randomised, placebo-controlled phase I trial [J].
Holmes, Clive ;
Boche, Delphine ;
Wilkinson, David ;
Yadegarfar, Ghasem ;
Hopkins, Vivienne ;
Bayer, Anthony ;
Jones, Roy W. ;
Bullock, Roger ;
Love, Seth ;
Neal, James W. ;
Zotova, Elina ;
Nicoll, James A. R. .
LANCET, 2008, 372 (9634) :216-223
[78]   CONSORT for reporting randomised trials in journal and conference abstracts [J].
Hopewell, Sally ;
Clarke, Mike ;
Moher, David ;
Wager, Elizabeth ;
Middleton, Philippa ;
Altman, Douglas G. ;
Schulz, Kenneth F. .
LANCET, 2008, 371 (9609) :281-283
[79]   The aging brain. Changes in the neuronal insulin/insulin receptor signal transduction cascade trigger late-onset sporadic Alzheimer disease (SAD). A mini-review [J].
Hoyer, S .
JOURNAL OF NEURAL TRANSMISSION, 2002, 109 (7-8) :991-1002
[80]   The overlap between neurodegenerative and vascular factors in the pathogenesis of dementia [J].
Iadecola, Costantino .
ACTA NEUROPATHOLOGICA, 2010, 120 (03) :287-296